MX2010008518A - Ciertas entidades quimicas, composiciones y metodos. - Google Patents

Ciertas entidades quimicas, composiciones y metodos.

Info

Publication number
MX2010008518A
MX2010008518A MX2010008518A MX2010008518A MX2010008518A MX 2010008518 A MX2010008518 A MX 2010008518A MX 2010008518 A MX2010008518 A MX 2010008518A MX 2010008518 A MX2010008518 A MX 2010008518A MX 2010008518 A MX2010008518 A MX 2010008518A
Authority
MX
Mexico
Prior art keywords
skeletal
methods
muscle
chemical entities
certain chemical
Prior art date
Application number
MX2010008518A
Other languages
English (en)
Spanish (es)
Inventor
Gustave Bergnes
Luke W Ashcraft
Jianchao Wang
Bradley P Morgan
Alex Muci
Zhe Yang
Scott Collibee
Jeff Gardina
Brian Stoltz
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of MX2010008518A publication Critical patent/MX2010008518A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Medicinal Preparation (AREA)
MX2010008518A 2008-02-04 2009-02-02 Ciertas entidades quimicas, composiciones y metodos. MX2010008518A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2606708P 2008-02-04 2008-02-04
PCT/US2009/000686 WO2009099594A1 (en) 2008-02-04 2009-02-02 Certain chemical entities, compositions and methods

Publications (1)

Publication Number Publication Date
MX2010008518A true MX2010008518A (es) 2010-11-10

Family

ID=40952391

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008518A MX2010008518A (es) 2008-02-04 2009-02-02 Ciertas entidades quimicas, composiciones y metodos.

Country Status (18)

Country Link
US (2) US7989469B2 (https=)
EP (1) EP2244711A4 (https=)
JP (1) JP2011510985A (https=)
KR (1) KR20100119773A (https=)
CN (1) CN101983061A (https=)
AR (1) AR072242A1 (https=)
AU (1) AU2009210787A1 (https=)
BR (1) BRPI0907502A2 (https=)
CA (1) CA2713864A1 (https=)
CL (1) CL2009000246A1 (https=)
CO (1) CO6290673A2 (https=)
EA (1) EA201001224A1 (https=)
EC (2) ECSP10010430A (https=)
IL (1) IL207367A0 (https=)
MX (1) MX2010008518A (https=)
TW (1) TW200946524A (https=)
WO (1) WO2009099594A1 (https=)
ZA (1) ZA201005780B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
EP2244711A4 (en) * 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
ES2547687T3 (es) * 2011-07-09 2015-10-08 Xuanzhu Pharma Co., Ltd. Forma cristalina I de sal de un inhibidor de dipeptidil-peptidasa IV y procedimiento de preparación y uso de la misma
BR112014000742A2 (pt) 2011-07-13 2016-08-23 Andrew A Wolff terapia de combinação de als
CA2869675C (en) * 2012-04-11 2022-06-14 Cytokinetics, Inc. Methods for improving resistance to skeletal muscle fatigue
SI3137622T1 (sl) 2014-04-29 2022-05-31 Cytokinetics, Inc. Postopki za zmanjšanje upada vitalne kapacitete
TWI794369B (zh) * 2017-12-14 2023-03-01 丹麥商Nmd藥品公司 用於治療神經肌肉病症的化合物
TW201927738A (zh) * 2017-12-14 2019-07-16 丹麥商Nmd藥品公司 用於治療神經肌肉病症的化合物
AU2020284742B2 (en) * 2019-05-28 2026-03-05 Mankind Pharma Ltd. Novel compounds for inhibition of Janus Kinase 1
WO2022234298A1 (en) * 2021-05-06 2022-11-10 Exscientia Ai Limited Pkc-theta modulators
CN118702622A (zh) * 2024-08-30 2024-09-27 阜新达得利化工股份有限公司 一种3-溴-2-氰基吡啶的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
WO2004043913A2 (en) 2002-11-08 2004-05-27 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
CN1816530A (zh) 2003-07-01 2006-08-09 麦克公司 用于治疗高眼压症的眼用组合物
JP2007515429A (ja) 2003-12-19 2007-06-14 エリクシアー ファーマシューティカルズ, インコーポレイテッド 障害を治療する方法
CA2553670A1 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
PL2069352T3 (pl) 2006-08-02 2014-03-31 Cytokinetics Inc Określone cząstki chemiczne, kompozycje i sposoby
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008075007A1 (en) * 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
EP2139478A4 (en) 2007-03-30 2010-05-05 Cytokinetics Inc CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
EP2244711A4 (en) * 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
US7998976B2 (en) 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
WO2010068483A2 (en) 2008-11-25 2010-06-17 University Of Rochester Mlk inhibitors and methods of use

Also Published As

Publication number Publication date
ZA201005780B (en) 2011-04-28
CN101983061A (zh) 2011-03-02
CA2713864A1 (en) 2009-08-13
ECSP10010430A (es) 2011-02-28
KR20100119773A (ko) 2010-11-10
EA201001224A1 (ru) 2011-08-30
EP2244711A4 (en) 2011-08-24
CO6290673A2 (es) 2011-06-20
AU2009210787A1 (en) 2009-08-13
AR072242A1 (es) 2010-08-18
EP2244711A1 (en) 2010-11-03
BRPI0907502A2 (pt) 2019-01-15
JP2011510985A (ja) 2011-04-07
IL207367A0 (en) 2010-12-30
WO2009099594A1 (en) 2009-08-13
CL2009000246A1 (es) 2009-06-26
TW200946524A (en) 2009-11-16
US20090253737A1 (en) 2009-10-08
ECSP10010432A (es) 2011-01-31
US20110312975A1 (en) 2011-12-22
US7989469B2 (en) 2011-08-02

Similar Documents

Publication Publication Date Title
MX2010008518A (es) Ciertas entidades quimicas, composiciones y metodos.
WO2008016648A3 (en) Certain chemical entities, compositions and methods
MX2009001170A (es) Determinadas entidades quimicas, composiciones y metodos.
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
MY157365A (en) Chemical compounds and uses
CY1113212T1 (el) Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 11-βητα υδροξυλ στεροειδους
JO3469B1 (ar) طافرات fgf21 واستخداماتها
EA201990619A1 (ru) Fgf21 мутанты и их применение
MX2011013903A (es) Polipeptidos quimericos y usos de los mismos.
EA024751B8 (ru) Мутанты fgf21 и их применение
UA104605C2 (uk) Аналоги глюкагону
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
BR112015024846A2 (pt) composições para utilização no estímulo do crescimento ósseo
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
PL2021337T3 (pl) Inhibitory dehydrogenazy 11-beta-hydroksysteroidowej typu 1
MY148079A (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
MX2009010049A (es) Metodos y composiciones para promover la salud de huesos y articulaciones.
MX2009003206A (es) Composiciones semejantes a azeotropo de 2-cloro-3,3,3,-trifluoropr open (hcfc-1233xf y 2-cloro-1,1,1,2-tetrafluoropropano (hcfc-244bb).
PH12014502286A1 (en) Improving resistance to skeletal muscle fatigue
EA019744B9 (ru) Изотиазолилоксифениламидины и их применение для борьбы с фитопатогенными грибами и семенной материал, обработанный изотиазолилоксифениламидинами
MX2010009883A (es) Acidos dicarboxilicos de cadena media, sus derivados y enfermedades metabolicas.
UY31877A (es) Péptidos específicos de los receptores de melanocortina para el tratamiento de la obesidad / 669
MX339753B (es) Composiciones vulcanizables basadas en cauchos de nitrilo que contienen grupos epoxi.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal